Insider Monkey
Piper Sandler Analysts Bullish on Allogene Therapeutics (ALLO) Ahead of Key ALPHA3 Data Readout
📈
AI Sentiment
Highly Positive
8/10
- Home
- ALLO
as of 03-23-2026 3:39pm EST
$2.46
+$0.39
+18.84%
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 539.4M | IPO Year: | 2018 |
| Target Price: | $8.40 | AVG Volume (30 days): | 4.3M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.87 | EPS Growth: | 34.09 |
| 52 Week Low/High: | $0.86 - $2.80 | Next Earning Date: | 03-12-2026 |
| Revenue: | N/A | Revenue Growth: | -100.00% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 140929.80% |
| P/E Ratio: | -2.38 | Index: | N/A |
| Free Cash Flow: | -149632000.0 | FCF Growth: | N/A |
AI-Powered ALLO Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 20 hours ago
AI Recommendation
hold
Model Accuracy: 79.39%
79.39%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Allogene Therapeutics Inc. (ALLO)
Chang David D
Sell
President and CEO
ALLO Mar 16, 2026
Avg Cost/Share
$2.47
Shares
47,763
Total Value
$117,974.61
Owned After
5,150,599
SEC Form 4
Beneski Benjamin Machinas
Sell
SVP, Chief Technical Officer
ALLO Mar 16, 2026
Avg Cost/Share
$2.47
Shares
4,835
Total Value
$11,942.45
Owned After
198,205
SEC Form 4
Beneski Benjamin Machinas
Sell
SVP, Chief Technical Officer
ALLO Mar 2, 2026
Avg Cost/Share
$2.60
Shares
7,132
Total Value
$18,543.20
Owned After
198,205
SEC Form 4
Douglas Earl Martin
Sell
SVP, General Counsel
ALLO Feb 2, 2026
Avg Cost/Share
$1.76
Shares
22,900
Total Value
$40,304.00
Owned After
564,948
SEC Form 4
Parker Geoffrey M.
Sell
CHIEF FINANCIAL OFFICER
ALLO Feb 2, 2026
Avg Cost/Share
$1.76
Shares
24,001
Total Value
$42,241.76
Owned After
1,252,795
SEC Form 4
Chang David D
Sell
President and CEO
ALLO Feb 2, 2026
Avg Cost/Share
$1.80
Shares
95,269
Total Value
$171,484.20
Owned After
5,150,599
SEC Form 4
Roberts Zachary
Sell
EVP of R&D
ALLO Feb 2, 2026
Avg Cost/Share
$1.77
Shares
35,700
Total Value
$63,189.00
Owned After
581,166
SEC Form 4
Yoshiyama Annie
Sell
SVP, Finance
ALLO Feb 2, 2026
Avg Cost/Share
$1.72
Shares
4,167
Total Value
$7,167.24
Owned After
130,322
SEC Form 4
Beneski Benjamin Machinas
Sell
SVP, Chief Technical Officer
ALLO Feb 2, 2026
Avg Cost/Share
$1.73
Shares
7,549
Total Value
$13,059.77
Owned After
198,205
SEC Form 4
Roberts Zachary
Sell
EVP of R&D
ALLO Jan 21, 2026
Avg Cost/Share
$1.56
Shares
26,269
Total Value
$40,979.64
Owned After
581,166
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Chang David D | ALLO | President and CEO | Mar 16, 2026 | Sell | $2.47 | 47,763 | $117,974.61 | 5,150,599 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Mar 16, 2026 | Sell | $2.47 | 4,835 | $11,942.45 | 198,205 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Mar 2, 2026 | Sell | $2.60 | 7,132 | $18,543.20 | 198,205 | |
| Douglas Earl Martin | ALLO | SVP, General Counsel | Feb 2, 2026 | Sell | $1.76 | 22,900 | $40,304.00 | 564,948 | |
| Parker Geoffrey M. | ALLO | CHIEF FINANCIAL OFFICER | Feb 2, 2026 | Sell | $1.76 | 24,001 | $42,241.76 | 1,252,795 | |
| Chang David D | ALLO | President and CEO | Feb 2, 2026 | Sell | $1.80 | 95,269 | $171,484.20 | 5,150,599 | |
| Roberts Zachary | ALLO | EVP of R&D | Feb 2, 2026 | Sell | $1.77 | 35,700 | $63,189.00 | 581,166 | |
| Yoshiyama Annie | ALLO | SVP, Finance | Feb 2, 2026 | Sell | $1.72 | 4,167 | $7,167.24 | 130,322 | |
| Beneski Benjamin Machinas | ALLO | SVP, Chief Technical Officer | Feb 2, 2026 | Sell | $1.73 | 7,549 | $13,059.77 | 198,205 | |
| Roberts Zachary | ALLO | EVP of R&D | Jan 21, 2026 | Sell | $1.56 | 26,269 | $40,979.64 | 581,166 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Mar 12, 2026 · 59% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLMar 12, 2026 · 59% conf.
AI Prediction SELL
1D
+1.34%
$2.52
Act: -3.61%
5D
-10.05%
$2.24
20D
-14.28%
$2.13
Price: $2.49 Prob +5D: 21% AUC: 1.000
0001628280-26-017230
allo-202603120001737287false00017372872026-03-122026-03-12
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026
Allogene Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3869382-3562771 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
210 East Grand Avenue, South San Francisco, California 94080 (Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (650) 457-2700 (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per shareALLOThe Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On March 12, 2026, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the fourth quarter and year ended December 31, 2025 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1Press Release of the Company, dated March 12, 2026.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALLOGENE THERAPEUTICS, INC.
By:/s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer
Dated: March 12, 2026
2025 Q3 Q3 2025 Earnings
8-K BUY Nov 6, 2025 · 100% conf.
2025
Q3
Q3 2025 Earnings
8-K BUYNov 6, 2025 · 100% conf.
AI Prediction BUY
1D
+2.67%
$1.09
Act: +10.91%
5D
+6.87%
$1.14
Act: +12.79%
20D
+5.48%
$1.12
Act: +34.41%
Price: $1.06 Prob +5D: 100% AUC: 1.000
0001628280-25-050227
allo-202511060001737287FALSE00017372872025-05-132025-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
Allogene Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3869382-3562771 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
210 East Grand Avenue, South San Francisco, California 94080 (Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (650) 457-2700 (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per shareALLOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On November 6, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended September 30, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1Press Release of the Company, dated November 6, 2025.
104The cover page of this report has been formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALLOGENE THERAPEUTICS, INC.
By:/s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer
Dated: November 6, 2025
2025 Q2 Q2 2025 Earnings
8-K Aug 13, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 13, 2025
0001737287-25-000087
allo-202508130001737287FALSE00017372872025-05-132025-05-13
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025
Allogene Therapeutics, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3869382-3562771 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
210 East Grand Avenue, South San Francisco, California 94080 (Address of principal executive offices including zip code) Registrant’s telephone number, including area code: (650) 457-2700 (Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. of Form 8-K): ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading Symbol(s) Name of each exchange on which registered
Common Stock, $0.001 par value per shareALLOThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On August 13, 2025, Allogene Therapeutics, Inc. (the “Company”) provided a corporate update and announced its financial results for the quarter ended June 30, 2025 in the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibit Number Description 99.1Press Release of the Company, dated August 13, 2025.
104The cover page of this report has been formatted in Inline XBRL.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
ALLOGENE THERAPEUTICS, INC.
By:/s/ David Chang, M.D., Ph.D. David Chang, M.D., Ph.D. President, Chief Executive Officer
Dated: August 13, 2025
Latest Allogene Therapeutics Inc. News
ALLO Breaking Stock News: Dive into ALLO Ticker-Specific Updates for Smart Investing
Compare ALLO vs Leading Stocks
See how ALLO stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ALLO Allogene Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.